Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Columbus Neuroscience LLC

Neither a doctor nor a teaching hospital

Research payments

$1,249,554

118 payments

Through program year 2024, Columbus Neuroscience LLC is reported as receiving $1,249,554 in research payments, across 118 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $24,789 2
2023 Research $367,423 8
2022 Research $312,735 31
2021 Research $402,835 31
2020 Research $141,773 46

Breakdown

Who paid Research payments · program years 2020–2024
  1. Eisai Inc. $604,493 54 payments
  2. F. Hoffmann-La Roche AG $348,654 33 payments
  3. Genzyme Corporation $256,846 22 payments
  4. Avanir Pharmaceuticals, Inc. $16,200 2 payments
  5. Hoffmann-La Roche Limited $12,863 4 payments
  6. Sanofi US Services Inc. $5,450 1 payment
  7. Novartis Pharmaceuticals Corporation $5,049 2 payments
Studies the money was for Research payments · program years 2020–2024
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $515,431 13 payments
  2. Second Phase III in RMS $283,824 20 payments
  3. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $237,676 15 payments
  4. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $89,062 41 payments
  5. Study of Ocrelizumab in PPMS Patients Assessing Upper Limb Function $64,829 13 payments
  6. Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis $24,620 8 payments
  7. 20-Avp-786-306 $16,200 2 payments
  8. Fen PH II RMS $12,863 4 payments
  9. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $4,589 1 payment
  10. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $460 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record